Want to see TSE:ZRO full AI Analyst Report?
Top Page
Biosenta Inc
(ZRO)
Select Model
Select Model
Rating:45Neutral
Price Target:
C$0.06
▲(5.00% Upside)
Action:Reiterated
Date:09/15/26
The score is held down primarily by very weak financial performance (persistent large losses, negative cash flow, and an equity deficit with high leverage versus assets). Technicals are only moderately supportive with short-term improvement but a still-weak long-term trend, while valuation is constrained by negative earnings and no dividend yield.
Positive Factors
Antimicrobial technology focus
A focused portfolio addressing microbial growth and odor control gives Biosenta a defined industry position and multiple potential application areas. If commercialization advances, product sales, licensing, and distribution arrangements could provide several routes to scale over the coming quarters.
Negative Factors
Severely stressed balance sheet
Debt that is many times the asset base, combined with negative and worsening shareholders’ equity, leaves Biosenta with very limited financial flexibility. This structure raises solvency and refinancing pressure and may constrain investment in commercialization over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Antimicrobial technology focus
A focused portfolio addressing microbial growth and odor control gives Biosenta a defined industry position and multiple potential application areas. If commercialization advances, product sales, licensing, and distribution arrangements could provide several routes to scale over the coming quarters.
Read all positive factors
Biosenta Inc (ZRO) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$2.26M
Dividend YieldN/A
Average Volume (3M)4.09K
Price to Earnings (P/E)―
Beta (1Y)1.67
Revenue GrowthN/A
EPS GrowthN/A
CountryCA
Employees5
SectorConsumer Defensive
Sector Strength42
IndustryHousehold & Personal Products
Share Statistics
EPS (TTM)-0.10
Shares Outstanding34,768,887
10 Day Avg. Volume4,388
30 Day Avg. Volume4,086
Financial Highlights & Ratios
PEG Ratio0.59
Price to Book (P/B)-0.40
Price to Sales (P/S)3296.23
P/FCF Ratio-8.29
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biosenta Inc Business Overview & Revenue Model
Company Description
Biosenta Inc., a Toronto-based Canadian firm established in 1986, specializes in the development, manufacturing, and sale of antimicrobial chemical compounds for both residential and commercial applications throughout the country. The company is a...
How the Company Makes Money
Biosenta’s expected revenue model is primarily derived from commercializing its antimicrobial/odor-control technologies through product sales and/or licensing arrangements. Potential revenue streams include (1) direct sales of antimicrobial and od...
Biosenta Inc Financial Statement Overview
Summary
Income Statement
6
Very Negative
Balance Sheet
8
Very Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.65K | 1.21K | 1.38K | 1.04K | 1.15K | 168.10K |
| Gross Profit | -2.32K | -1.78K | 835.00 | 427.00 | 728.00 | 99.11K |
| EBITDA | -1.52M | -1.39M | -1.09M | -6.24M | -1.24M | -2.03M |
| Net Income | -2.58M | -2.51M | -2.23M | -6.30M | -1.46M | -2.05M |
Balance Sheet | ||||||
| Total Assets | 102.30K | 110.33K | 113.54K | 107.59K | 256.08K | 263.66K |
| Cash, Cash Equivalents and Short-Term Investments | 19.93K | 26.49K | 8.53K | 5.88K | 27.26K | 111.88K |
| Total Debt | 7.52M | 694.59K | 5.55M | 5.62M | 94.77K | 152.43K |
| Total Liabilities | 11.89M | 10.17M | 7.99M | 7.96M | 3.18M | 2.86M |
| Stockholders Equity | -11.78M | -10.06M | -7.88M | -7.86M | -2.92M | -2.59M |
Cash Flow | ||||||
| Free Cash Flow | -462.73K | -481.24K | -779.35K | -566.35K | -504.43K | -672.29K |
| Operating Cash Flow | -461.07K | -455.38K | -779.35K | -550.79K | -504.43K | -672.29K |
| Investing Cash Flow | -1.65K | -25.86K | 0.00 | -15.56K | 0.00 | 0.00 |
| Financing Cash Flow | 477.97K | 499.20K | 781.99K | 544.97K | 419.81K | 739.86K |
Biosenta Inc Technical Analysis
Positive
0.06
Price Trends
0.05
Positive
0.05
Positive
0.07
Negative
Market Momentum
>-0.01
Positive
55.24
Neutral
29.17
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:ZRO, the sentiment is Positive. The current price of 0.06 is above the 20-day moving average (MA) of 0.06, above the 50-day MA of 0.05, and below the 200-day MA of 0.07, indicating a neutral trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 55.24 is Neutral, neither overbought nor oversold. The STOCH value of 29.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:ZRO.
Biosenta Inc Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
46 Neutral | C$1.89M | 11.90 | 0.38% | ― | -87.74% | -220.61% | |
45 Neutral | C$2.26M | -0.63 | 23.72% | ― | ― | ― | |
42 Neutral | C$2.04M | -0.29 | -196.58% | ― | 65.29% | -1.78% | |
39 Underperform | C$13.28M | -11.91 | -147.81% | ― | ― | -65.67% |
* Consumer Defensive Sector Average
TSE:ZRO
Biosenta Inc
0.07
-0.08
-53.57%
TSE:BGA
BioNeutra Global
0.03
0.00
0.00%
TSE:LFST
Lifeist Wellness
0.05
-0.02
-33.33%
TSE:PSYC
Psyched Wellness
0.01
-0.01
-50.00%
TSE:MOOO.X
Happy Supplements Inc.
0.35
-0.19
-35.19%
TSE:URAI
Pure to Pure Beauty Inc.
0.11
-0.04
-26.67%
Biosenta Inc Corporate Events
Business Operations and StrategyProduct-Related Announcements
Biosenta Launches TRUE Disinfectant Pilot with Dynamic Facility Services
Positive
Sep 1, 2026
Biosenta Inc. has signed a memorandum of understanding with British Columbia-based Dynamic Facility Services to run a pilot program using Biosenta’s TRUE disinfectant in Dynamic’s commercial cleaning operations. The initiative will ass...
Business Operations and StrategyProduct-Related Announcements
Biosenta Highlights Tri-Filler Antimicrobial Technology in High-Level University of Calgary Visit
Positive
Aug 14, 2026
Biosenta Inc. showcased its Tri-Filler™ antimicrobial technology during a visit by Secretary of State (International Development) Randeep Sarai to the University of Calgary research facilities. The tour highlighted the company’s collab...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.